Labcorp Holdings Valuation

Is 0JSY undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0JSY when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 0JSY ($194) is trading below our estimate of fair value ($536.2)

Significantly Below Fair Value: 0JSY is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0JSY?

Other financial metrics that can be useful for relative valuation.

0JSY key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue1.8x
Enterprise Value/EBITDA13.9x
PEG Ratio2.2x

Price to Earnings Ratio vs Peers

How does 0JSY's PE Ratio compare to its peers?

The above table shows the PE ratio for 0JSY vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average31.9x
IDHC Integrated Diagnostics Holdings
12.2x25.5%US$192.6m
SN. Smith & Nephew
42.8x21.7%UK£8.9b
MDC Mediclinic International
21.9x10.7%UK£3.7b
CTEC ConvaTec Group
50.7x20.7%UK£5.2b
0JSY Labcorp Holdings
41.5x19.1%US$16.6b

Price-To-Earnings vs Peers: 0JSY is expensive based on its Price-To-Earnings Ratio (41.5x) compared to the peer average (35.1x).


Price to Earnings Ratio vs Industry

How does 0JSY's PE Ratio compare vs other companies in the European Healthcare Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a18.8%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a18.8%
n/an/an/a
No more companies

Price-To-Earnings vs Industry: 0JSY is expensive based on its Price-To-Earnings Ratio (41.5x) compared to the European Healthcare industry average (18.8x).


Price to Earnings Ratio vs Fair Ratio

What is 0JSY's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0JSY PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio41.5x
Fair PE Ratio42.2x

Price-To-Earnings vs Fair Ratio: 0JSY is good value based on its Price-To-Earnings Ratio (41.5x) compared to the estimated Fair Price-To-Earnings Ratio (42.2x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0JSY forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$194.00
US$237.47
+22.4%
7.2%US$262.00US$210.00n/a15
Jun ’25US$192.43
US$238.47
+23.9%
6.7%US$262.00US$210.00n/a15
May ’25US$201.65
US$239.57
+18.8%
6.8%US$262.00US$210.00n/a16
Apr ’25US$217.79
US$244.87
+12.4%
6.0%US$270.00US$220.00n/a15
Mar ’25US$216.78
US$245.07
+13.0%
6.0%US$270.00US$220.00n/a15
Feb ’25US$223.71
US$241.28
+7.9%
6.8%US$270.00US$215.00n/a14
Jan ’25US$227.25
US$242.28
+6.6%
6.3%US$270.00US$215.00n/a14
Dec ’24US$219.15
US$239.92
+9.5%
7.1%US$270.00US$210.00n/a14
Nov ’24US$204.86
US$239.56
+16.9%
7.5%US$270.00US$210.00n/a14
Oct ’24US$203.81
US$245.85
+20.6%
8.6%US$285.00US$210.00n/a14
Sep ’24US$212.17
US$249.28
+17.5%
7.5%US$285.00US$215.00n/a14
Aug ’24US$211.71
US$255.64
+20.8%
9.0%US$290.00US$215.00n/a14
Jul ’24US$239.41
US$269.14
+12.4%
7.2%US$290.00US$233.00n/a14
Jun ’24US$214.45
US$271.86
+26.8%
6.1%US$290.00US$235.00US$192.4314
May ’24US$225.99
US$276.50
+22.3%
6.7%US$300.00US$235.00US$201.6514
Apr ’24US$227.86
US$284.31
+24.8%
4.3%US$300.00US$260.00US$217.7913
Mar ’24US$239.25
US$285.54
+19.3%
4.6%US$304.00US$260.00US$216.7813
Feb ’24US$251.02
US$279.15
+11.2%
7.6%US$315.00US$250.00US$223.7113
Jan ’24US$234.66
US$276.23
+17.7%
7.7%US$315.00US$250.00US$227.2513
Dec ’23US$242.94
US$278.15
+14.5%
7.2%US$315.00US$250.00US$219.1513
Nov ’23US$223.17
US$281.92
+26.3%
6.7%US$315.00US$260.00US$204.8613
Oct ’23US$209.01
US$299.92
+43.5%
5.4%US$320.00US$265.00US$203.8113
Sep ’23US$230.55
US$299.92
+30.1%
5.4%US$320.00US$265.00US$212.1713
Aug ’23US$261.14
US$299.92
+14.9%
5.4%US$320.00US$265.00US$211.7113
Jul ’23US$235.32
US$302.71
+28.6%
10.5%US$350.00US$215.00US$239.4114
Jun ’23US$256.55
US$305.14
+18.9%
10.8%US$350.00US$215.00US$214.4514

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.